• Subscribe to Huron Insights
  • Submit RFP
  • Investor Relations
  • Careers
  • Contact Us

  • Industry
    • Aerospace
    • Automotive
    • Energy & Utilities
    • Financial Services
    • Government
    • Healthcare
    • Higher Education
    • Hospitality & Gaming
    • Life Sciences
    • Logistics
    • Manufacturing
    • Metals & Mining
    • Retail & Consumer Products
    • Technology, Media & Telecommunications
  • Expertise
    • Business Advisory
    • Enterprise Solutions & Analytics
    • Technology
  • Resources
  • Company
    • About Us
    • Contact Us
    • Locations
    • Our Experts
    • Leadership
    • Press Releases
    • Diversity & Community Affairs
    • Careers
HigherEd_ThoughtLeadership_Resize

Clinical Research Management Briefing – February 26, 2018

Top Stories

CRISPR Could End Sickle Cell Disease, But Signing Up Black Patients for Clinical Trials Will Be a Hard Sell

A history of unethical biomedical treatment in African-American communities could make recruiting patients difficult for researchers.

STAT, February 21

Trump Pushing Ahead on Koch-Backed Experimental Drugs 'Right to Try' Agenda

Bypassing the Food and Drug Administration's clinical-trial process is raising safety and ethical concerns among patient-advocacy organizations.

CNBC, February 21

 

Huron Spotlight

Emory University Goes Live on Huron IACUC 8.1

In just five months, Emory University deployed Huron IACUC to streamline operations and better manage its protocols.

Huron

 

Financial and Operations

Distributed Ledgers Can Streamline Clinical Trials

New technology has the potential to streamline healthcare processes – bringing new drugs to the market faster and at a lower price.

Nasdaq, February 15

 

Technology

Sensors and Wearables Transform Clinical Trials but Challenges Remain, Experts Say

Inconsistencies in the way devices measure, report and collect data make selecting the right device even more important.

CenterWatch, February 19

 

Pharma/Bio-Tech

What Pharma Companies Need to Know about FDA's New Draft IVD Guidance

With the increased use of in vitro diagnostics (IVDs), pharmaceutical and biotech companies need to develop guidelines for risk evaluation and consideration.

Applied Clinical Trials, February 12

Contact Us

Related Articles

  • Clinical Research Management Briefing – February 19, 2018
  • Clinical Research Management Briefing – February 12, 2018
  • Clinical Research Management Briefing – February 5, 2018
Share:

Subscribe to Huron Insights

Sign Up Today!

Clinical Research Management Briefing – February 26, 2018

  • Rick Rohrbach

    Rick Rohrbach

    Managing Director

    Industry:

    Higher Education | Healthcare | Technology Media and Telecommunications | Life Sciences | Retail

    Contact Me LinkedIn Read My Bio
  • Leah Guidry

    Leah Guidry

    Managing Director

    Industry:

    Higher Education | Healthcare | Life Sciences

    Contact Me LinkedIn Read My Bio
  • Facebook Icon
  • Google Plus Icon
  • Linkedin Icon
  • Twitter Icon

© 2019 Huron Consulting Group Inc. and affiliates. All rights reserved. Huron is a global consultancy and not a CPA firm, and does not provide attest services, audits, or other engagements in accordance with standards established by the AICPA or auditing standards promulgated by the Public Company Accounting Oversight Board ("PCAOB"). Huron is the trading name of Pope Woodhead & Associates Ltd.

We use cookies on our website to provide you with a more personalized digital experience, enable website functionality and understand the performance of our site. You may review our Privacy Statement and our Cookies Policy. By using this site you agree to our use of cookies. I Accept

  • Privacy Statement
  • Terms & Conditions
  • Cookies Policy
  • Fraudulent Offers